Background: Severe disorders of consciousness (sDoC) are a common sequela of aneurysmal subarachnoid hemorrhages (aSAH), and amantadine has been used to improve cognitive recovery after traumatic brain injury.

Objective: This study evaluated the effect of amantadine treatment on consciousness in patients with sDoC secondary to aSAH.

Methods: This double-center, randomized, prospective, cohort study included patients ≥ 18 years old with sDoC after aSAH from February 2020 to September 2023. Individual patient data of patients were pooled to determine the effect of amantadine, in comparison to placebo. The primary outcomes at 3 and 6 months after the ictus were evaluated using the modified Rankin scale (mRS) and Glasgow outcome scale (GOS). In addition to all-cause mortality, secondary endpoints were assessed weekly during intervention by scores on Rappaport's Disability Rating Scale (RDRS) and Coma Recovery Scale-Revised (CRSR).

Results: Overall, 37 patients with sDoC and initial Glasgow Coma Scale (GCS) varying between 3 and 11 were recruited and randomized to amantadine (test group, n = 20) or placebo (control group, n = 17). The average age was 59.5 years (28 to 81 year-old), 24 (65%) were women, and the mean GCS at the beginning of intervention was 7.1. Most patients evolved to vasospasm (81%), with ischemia in 73% of them. The intervention was started between 30 to 180 days after the ictus, and administered for 6 weeks, with progressively higher doses. Neither epidemiological characteristics nor considerations regarding the treatment of the aneurysm and its complications differed between both arms. Overall mortality was 10.8% (4 deaths). During the study, four patients had potential adverse drug effects: two presented seizures, one had paralytic ileus, and another evolved with tachycardia; the medication was not suspended, only the dose was not increased. At data opening, 2 were taking amantadine and 2 placebo.

Conclusion: Despite some good results associated with amantadine in the literature, this study did not find statistically significant positive effects in cognitive recovery in patients with delayed post-aSAH sDoC. Further large randomized clinical trials in patients' subgroups are needed to better define its effectiveness and clarify any therapeutic window where it can be advantageous.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2024.108135DOI Listing

Publication Analysis

Top Keywords

cognitive recovery
12
amantadine improve
8
improve cognitive
8
severe disorders
8
disorders consciousness
8
aneurysmal subarachnoid
8
patients sdoc
8
amantadine
7
patients
7
study
5

Similar Publications

Piloting a minimum data set for older people living in care homes in England: a developmental study.

Age Ageing

January 2025

Centre for Research in Public Health and Community Care (CRIPACC), University of Hertfordshire, College Lane, Hatfield, UK.

Background: We developed a prototype minimum data set (MDS) for English care homes, assessing feasibility of extracting data directly from digital care records (DCRs) with linkage to health and social care data.

Methods: Through stakeholder development workshops, literature reviews, surveys and public consultation, we developed an aspirational MDS. We identified ways to extract this from existing sources, including DCRs and routine health and social care datasets.

View Article and Find Full Text PDF

Background: The COVID-19 pandemic caused social and economic damages, increased mortality rates, and psychological damages such as fear, stress, anxiety, and depression. Therefore, the present study aimed to explore the perceptions and experiences of COVID-19 survivors diagnosed with anxiety and depression, along with one of their family members in Ahvaz.

Materials And Methods: A qualitative study was conducted on 50 COVID-19 survivors and their family members using an in-depth interview and a purposive sampling method in 2022.

View Article and Find Full Text PDF

Feeding and eating disorders (FEDs) are a heterogeneous grouping of disorders at the mind-body interface, with typical onset from childhood into emerging adulthood. They occur along a spectrum of disordered eating and compensatory weight management behaviors, and from low to high body weight. Psychiatric comorbidities are the norm.

View Article and Find Full Text PDF

Five-Year Outcomes of a School-Based Personality-Focused Prevention Program on Adolescent Substance Use Disorder: A Cluster Randomized Trial.

Am J Psychiatry

January 2025

Department of Psychiatry and Addiction, Faculty of Medicine, University of Montreal, Montreal (Conrod, Seguin, Lynch); CHU Sainte-Justine Mother-Child University Hospital, Montreal (Conrod, Seguin, Masse, Spinney, Lynch); Department of Psychiatry and Department of Community Health and Epidemiology, Faculty of Medicine, and Department of Psychology and Neuroscience, Faculty of Science, Dalhousie University, Halifax, Canada (Stewart); Department of Psychology, Faculty of Arts and Science, McGill University, Montreal (Pihl); School of Public Health, University of Montreal, Montreal (Masse).

Objective: Rates of substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. This study investigated the 5-year SUD outcomes following a selective drug and alcohol prevention program targeting personality risk factors for adolescent substance misuse.

Methods: The Co-Venture trial is a cluster randomized trial involving 31 high schools in the greater Montreal area that agreed to conduct annual health behavior surveys for 5 years on the entire 7th grade cohort of assenting students enrolled at the school in 2012 or 2013.

View Article and Find Full Text PDF

Objective: The first-episode psychosis (FEP) and clinical high-risk (CHR) team within the child and adolescent mental health (CAMH) service receives referrals by psychiatric units, CAMH service, schools, and general practitioners. This audit evaluated the implementation of the FEP-CHR team in Ferrara, Italy.

Methods: The FEP-CHR team provides standardised assessment and up to 2-year individualised treatment including pharmacological prescription, cognitive-behavioral psychotherapy, and vocational activities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!